MIRA Pharmaceuticals jumps on positive preclinical data from marijuana-based pain relief drug
Shares of drug developer MIRA Pharmaceuticals MIRA.O rise 45.9% to $1.81 in extended trading
Company says its experimental drug, Mira-55, a non-psychoactive marijuana analog showed morphine-comparable pain relief in a preclinical animal trial
Mira-55 is a synthetic analog of marijuana designed to target CB2 receptors, which are associated with anti-inflammatory effects - MIRA
In the trial the drug significantly reduced pain sensitivity and showed efficacy comparable to morphine, the opioid control - company
Company says it previously received confirmation from the U.S. Drug Enforcement Administration that Mira-55 is not classified as a controlled substance, removing a key regulatory barrier to clinical development
Company adds it continues to advance Mira-55 towards human trials
Up to last close, stock up 8.8% YTD
Related Articles
The Magnificent Seven: What They Are, How They Performed in 2025, and Which Will Be the Best in 2026?
TradingKey - The Magnificent Seven refers to the seven best tech stocks in 2023. These are Apple (AAPL), Microsoft (MSFT), Alphabet (GOOG) (GOOGL), Amazon (AMZN), Nvidia (NVDA), Meta Platforms (META), and Tesla (TSLA). These technology titans are developing products related to Artificial Intelligenc
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to ma
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.
